A human subject has been injected with an AI-designed virus aiming to kill antibiotic-resistant bacteria, so let's see how that turns out

Date:
Fri, 30 Oct 2026 23:05:00 +0000

Description:
An AI lab designed a virus, put it in a sick person, and then declined to say what happened.

FULL STORY ======================================================================Copy link Facebook X Whatsapp Reddit Pinterest Flipboard Threads Email Share this article 0 Join the conversation Follow us Add us as a preferred source on Google Newsletter Subscribe to our newsletter San Francisco lab Radical Numerics says its Omnii-1 model designed bacteriophages that were given to a patient with a drug-resistant infection, a world first The phages were built by rewriting the gene for T7's tail fiber, the protein the virus uses to
latch onto bacteria Nobody outside the company knows whether it worked, because the results have not been published, peer-reviewed, or disclosed yet Radical Numerics has announced its AI-designed viruses (bacteriophages) were given to a sick person, but has not provided much further insight about what happened next.

The San Francisco AI lab announced in October 2026 that bacteriophages designed by its new genome model had been administered to a human patient
with an antibiotic-resistant bacterial infection, under a physician-led compassionate-use pathway authorized by the FDA. If the claim holds, it is
the first time an AI-designed organism of any kind has been put into a person as medicine. Latest Videos From TechRadar Watch full video here: Not a new phenomenon, but one that could do with AI assistance Bacteriophages are viruses that infect bacteria and ignore human cells entirely. They have been used as therapy for more than a century, predating penicillin, and have enjoyed a quiet revival as antibiotics have begun to fail.

The World Health Organization considers phage therapy broadly safe, and
unlike broad-spectrum antibiotics, a phage can target one bacterial strain while leaving the rest of your microbiome alone. You may like How can AI help stop the next global disease outbreak before it kills millions? When the attacker has no human left to catch The hidden risks of AI's increasingly helpful agents

That precision is also the problem: each phage recognizes a narrow set of bacterial surface receptors, so treating a patient means finding one that matches their specific infection. Clinicians screen existing phage libraries, then environmental samples, then give up and try engineering as a last
resort. For someone with sepsis, that search is not an academic exercise but an important life-or-death situation.

The scale of the underlying problem is not in dispute. The Global Burden of Disease project estimated that antimicrobial resistance was associated with roughly 4.7 million deaths in 2021, with projections indicating that between 2025 and 2050, close to 40 million deaths could be attributable to it. Are
you a pro? Subscribe to our newsletter Sign up to the TechRadar Pro
newsletter to get all the top news, opinion, features and guidance your business needs to succeed! Contact me with news and offers from other Future brands Receive email from us on behalf of our trusted partners or sponsors By submitting your information you agree to the Terms & Conditions and Privacy Policy and are aged 16 or over.

Radical Numerics was founded by members of the team behind Evo and Evo 2, the Arc Institute genome models that generated the first entirely AI-written
phage genomes . That earlier work produced 700,000 candidate genomes; 285
were synthesized, and 16 produced viable viruses. It was a proof of concept with a punishing, yet promising hit rate.

Omnii-1 is the follow-up, and the company's technical write-up describes a narrower, more surgical approach. Rather than inventing whole genomes, the model edits the targeting component. The team worked with T7, a well-characterized 40-kilobase E. coli phage, and rewrote gp17, the receptor-binding tail fiber.

The numbers the company is willing to share are genuinely interesting. At 11 to 15 amino acid changes from wild type, 69.9% of designed variants were recovered as viable phages, against 4.8% for random controls. Of 6,694 variants with measurable activity, 2,161 beat the original, including some carrying 28 amino acid substitutions. What to read next OpenAI tries to build a persona that makes it our equal, and yes, now even I'm very worried 5
things you need to know about the big AI 'slowdown' battle 'This situation is obviously unacceptable': OpenAI agent allegedly hacks Australian government healthcare website A promising, but unproven and unpublished play The company tested its designed cocktail against bacteria isolated from a real patient's infection, confirmed it eliminated that isolate in vitro, and then administered it. The patient reportedly had an E. coli infection that had resisted not only antibiotics but every available phage, which is effectively the worst position one can be in when it comes to infectious diseases.

Radical Numerics has since declined to describe the patient's clinical
course, outcome, hospital, or physicians, citing patient privacy and the fact that even limited clinical detail could identify the patient.

The company self-published the technical report on its website and has not
had it peer-reviewed, but has separately indicated the treatment is proprietary and something it hopes to commercialize.

That silence held as of October 29, nine days after the announcement, when trade coverage for infectious disease clinicians still reported no disclosed clinical course, no outcome, and no peer-reviewed publication. The technical write-up remains the only account of the case.

In fairness to Radical Numerics, its own write-up states plainly that single-patient observations cannot establish safety or efficacy, which is
more cautionary than most product launches manage. CEO Eric Nguyen has also said the company intends to publish through peer review.

Outside experts have landed somewhere between intrigued and unconvinced,
which is the correct place to land. Harvard microbiologist Michael Baym, who was not involved, said the result would be incredible if it works, but added that his instinct is skepticism until the treatment finishes and the viruses' novelty can actually be examined.

The commercial logic is much easier to establish; phage hunting is slow, and Radical Numerics believes it can compress design to days rather than months.

Ottawa Hospital infectious disease clinician Marisa Azad, who is
collaborating with the company, has described the conventional search as remarkably time-consuming, and she is not wrong. If AI can reliably shorten that loop, it changes who gets treated in time, allowing for a more cost-effective and broader audience for said treatments.

There is cause for some concern too: a model that can design viruses to order is, structurally, a model that can design viruses to order. Radical Numerics acknowledges this directly by committing to biosafety, containment, and data-sharing measures scaled to the model's capability.

It is the same dual-use problem that has dogged every capable biological design tool, and one that AI labs have been publicly wrestling with as their systems get better at biology.

Engineered phages have reached patients before, most famously a 2019 case in which modified phages treated a disseminated drug-resistant Mycobacterium abscessus infection. What is new here is not the therapeutic concept but the design process, and the governance questions attach to the AI-driven process, not the concept itself.

AI has moved from reading biology to writing it and handing the result to a doctor. That is a different category of claim than an AI model proposing a cancer hypothesis or outperforming specialists on rare-disease diagnosis , both of which keep a human firmly in the loop before anything enters a bloodstream.

For now, however, a very clever experiment was run on a very sick person, and we still don't know how it went or when somebody decides to tell us. If it does pan out however, it will have massive rammifications for an industry
that is only expected to grow across the next few decades. Follow TechRadar
on Google News and add us as a preferred source to get our expert news, reviews, and opinion in your feeds.



======================================================================
Link to news story: https://www.techradar.com/pro/a-human-subject-has-been-injected-with-an-ai-des igned-virus-aiming-to-kill-antibiotic-resistant-bacteria-so-lets-see-how-that- turns-out


--- Mystic BBS v1.12 A49 (Linux/64)
* Origin: tqwNet Technology News (1337:1/100)